文献速递抗栓抗凝管理药物不良反应与药物警戒

EMPIRE真实世界数据:抗纤维化治疗的IPF患者抗凝药使用与出血风险

Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE.
PubMed 文献 · Drug Saf · 2020-01-01

基于EMPIRE注册研究2794例IPF患者,分析抗凝/抗血小板治疗与抗纤维化药物相关出血事件。总体出血发生率0.29%(尼达尼布0.25%,吡非尼酮0.04%),与是否接受抗凝或抗血小板治疗无关(P=0.072)。接受抗凝治疗者尼达尼布使用比例较低。

要点

  • IPF患者抗纤维化治疗总体出血发生率低(0.29%)
  • 出血发生率与抗凝或抗血小板治疗无关(P=0.072)
  • 接受抗凝治疗的患者尼达尼布使用频率较低

核心结论

  • EMPIRE真实世界数据显示IPF患者抗纤维化治疗总体出血发生率低,且与是否接受抗凝或抗血小板治疗无关(P=0.072)。
  • 接受抗凝药物治疗的患者尼达尼布使用频率较低,可能与其作用机制有关。

研究设计与样本

  • 欧洲多中心IPF注册研究(EMPIRE)纳入2794例IPF患者,按治疗分为四组:A组无抗凝或抗血小板治疗(1828例)、B组抗凝治疗(227例)、C组抗血小板治疗(659例)、D组抗凝联合抗血小板治疗(80例)。
  • 总体673例(24.1%)接受尼达尼布,933例(33.4%)接受吡非尼酮。
  • 研究表征出血事件及其与抗纤维化和抗凝治疗的关系。

主要发现

  • A组患者较B、C、D组更年轻且合并症率通常最低。
  • A组和C组中接受尼达尼布的患者比例高于B组;吡非尼酮在D组最常见,各组间分布较均衡。
  • 报告出血事件的患者中,8例中有7例接受尼达尼布(分布于A、C、D组)。
  • 出血发生率分别为A组3.0/10000患者年、B组0/10000患者年、C组1.3/10000患者年、D组18.1/10000患者年。
  • 总体出血发生率为0.29%(尼达尼布0.25%;吡非尼酮0.04%),与是否接受抗凝或抗血小板治疗无关(P=0.072)。

临床怎么用

  • 真实世界数据显示IPF患者接受抗纤维化治疗时出血风险总体较低,合并抗凝或抗血小板治疗未显著增加出血发生率。
  • 临床对接受抗凝治疗的患者处方尼达尼布可能更为谨慎,但需结合个体出血风险综合评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Nintedanib, a tyrosine kinase receptor inhibitor, may be associated with increased bleeding risk. Thus, patients with an inherited predisposition to bleeding, or those receiving therapeutic doses of anticoagulants or high-dose antiplatelet therapy, have been excluded from clinical trials of nintedanib in idiopathic pulmonary fibrosis (IPF). OBJECTIVE: Our objective was to examine real-world bleeding events in patients with IPF treated with antifibrotics, including those receiving anticoagulants and/or antiplatelet therapy. METHODS: The European MultiPartner IPF Registry (EMPIRE) enrolled 2794 patients with IPF: group A (1828: no anticoagulant or antiplatelet treatment), group B (227: anticoagulant treatment), group C (659: antiplatelet treatment), and group D (80: anticoagulant and antiplatelet treatment). Overall, 673 (24.1%) received nintedanib and 933 (33.4%) received pirfenidone. Bleeding events and their relationship to antifibrotic and anticoagulation treatment were characterized. RESULTS: Group A patients, versus those in groups B, C, and D, were typically younger and generally had the lowest comorbidity rates. A higher proportion of patients in groups A and C, versus group B, received nintedanib. Pirfenidone, most common in group D, was more evenly balanced across groups. In patients with reported bleeding events, seven of eight received nintedanib (groups A, C, and D). Bleeding incidence was 3.0, 0, 1.3, and 18.1 per 10,000 patient-years (groups A, B, C, and D, respectively). CONCLUSION: Real-world data from EMPIRE showed that patients on anticoagulant medications received nintedanib less frequently, perhaps based on its mechanism of action. Overall, bleeding incidence was low (0.29%: nintedanib 0.25%; pirfenidone 0.04%) and irrespective of anticoagulant or antiplatelet therapy received (P = 0.072).

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Kolonics-Farkas AM, Šterclová M, Mogulkoc N, et al. Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE. Drug Saf. 2020. PMID: 32734423. doi:10.1007/s40264-020-00978-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。